Ulrich Andergassen
Ludwig Maximilian University of Munich
91 Papers
421 Citations
Ulrich Andergassen is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Breast cancer & Circulating tumor cell. The author has an hindex of 21, co-authored 91 publications.
Chat about Author
Papers
Molecular profiling of single circulating tumor cells with diagnostic intention
Bernhard Polzer,Gianni Medoro,Sophie Pasch,Francesca Fontana,Laura Zorzino,Aurelia Pestka,Ulrich Andergassen,Franziska Meier-Stiegen,Zbigniew T. Czyż,Zbigniew T. Czyż,Barbara Alberter,Steffi Treitschke,Thomas Schamberger,M. Sergio,Giulia Bregola,Anna Doffini,Stefano Gianni,Alex Calanca,Giulio Signorini,Chiara Bolognesi,Arndt Hartmann,Peter A. Fasching,Maria T. Sandri,Brigitte Rack,Tanja Fehm,Giuseppe Giorgini,Nicolò Manaresi,Christoph Klein,Christoph Klein +28 more
TL;DR: Microheterogeneity analysis among individual CTCs uncovered pre‐existing cells resistant to ERBB2‐targeted therapies suggesting ongoing microevolution at late‐stage disease whose exploration may provide essential information for personalized treatment decisions and shed light into mechanisms of acquired drug resistance.
260
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
Kristen S. Purrington,Susan L. Slager,Diana Eccles,Drakoulis Yannoukakos,Peter A. Fasching,Peter A. Fasching,Penelope Miron,Jane Carpenter,Jenny Chang-Claude,Nicholas G. Martin,Grant W. Montgomery,Vessela N. Kristensen,Hoda Anton-Culver,Paul J. Goodfellow,William J. Tapper,Sajjad Rafiq,S Gerty,Lorraine Durcan,Irene Konstantopoulou,Florentia Fostira,Athanassios Vratimos,Paraskevi Apostolou,Irene Konstanta,Vassiliki Kotoula,Sotiris Lakis,Meletios A. Dimopoulos,Dimosthenis Skarlos,Dimitrios Pectasides,George Fountzilas,Matthias W. Beckmann,Alexander Hein,Matthias Ruebner,Arif B. Ekici,Arndt Hartmann,Ruediger Schulz-Wendtland,Stefan P. Renner,Wolfgang Janni,Brigitte Rack,Christoph Scholz,Julia Neugebauer,Ulrich Andergassen,Michael P. Lux,Lothar Haeberle,Christine L. Clarke,Nirmala Pathmanathan,Anja Rudolph,Dieter Flesch-Janys,Stefan Nickels,Janet E. Olson,James N. Ingle,Curtis Olswold,Seth W. Slettedahl,Jeanette E. Eckel-Passow,S. Keith Anderson,Daniel W. Visscher,Victoria Cafourek,Hugues Sicotte,Naresh Prodduturi,Elisabete Weiderpass,Leslie Bernstein,Argyrios Ziogas,Jennifer Ivanovich,Graham G. Giles,Laura Baglietto,Melissa C. Southey,Veli-Matti Kosma,Hans Fischer,MW Reed,Simon S. Cross,Sandra Deming-Halverson,Martha J. Shrubsole,Qiuyin Cai,Xiao-Ou Shu,Mary B. Daly,Jo Ellen Weaver,Eric A. Ross,Jennifer R. Klemp,Priyanka Sharma,Diana Torres,Diana Torres,Thomas Rüdiger,Heidrun Wölfing,Hans Ulrich Ulmer,Asta Försti,Asta Försti,Thaer Khoury,Shicha Kumar,Robert Pilarski,Charles L. Shapiro,Dario Greco,Päivi Heikkilä,Kristiina Aittomäki,Carl Blomqvist,Astrid Irwanto,Jianjun Liu,Vernon S. Pankratz,Xianshu Wang,Gianluca Severi,Arto Mannermaa,Douglas F. Easton,Per Hall,Hiltrud Brauch,Angela Cox,Wei Zheng,Andrew K. Godwin,Ute Hamann,Christine B. Ambrosone,Amanda E. Toland,Heli Nevanlinna,Celine M. Vachon,Fergus J. Couch +110 more
TL;DR: A polygenic risk score (PRS) for TN breast cancer based on known breast cancer risk variants showed a 4-fold difference in risk between the highest and lowest PRS quintiles, suggesting that genetic variation may be used for TN Breast cancer risk prediction.
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Elisabeth Trapp,Elisabeth Trapp,Wolfgang Janni,Christian Schindlbeck,Julia Jückstock,Ulrich Andergassen,Amelie de Gregorio,Marianna Alunni-Fabbroni,M Tzschaschel,Arkadius Polasik,Julian Koch,Thomas W. P. Friedl,Peter A. Fasching,Lothar Haeberle,Tanja Fehm,Andreas Schneeweiss,Matthias W. Beckmann,Klaus Pantel,Volkmar Mueller,Brigitte Rack,Christoph Scholz +20 more
TL;DR: The presence of CTCs 2 years after chemotherapy was associated with decreased OS and DFS, and active individualized surveillance strategies for breast cancer survivors based on biomarkers should be reconsidered.
126
Detection of circulating tumor cells in different stages of prostate cancer.
Mark Thalgott,Brigitte Rack,Tobias Maurer,Michael Souvatzoglou,Matthias Eiber,Veronika Kreß,Matthias Heck,Ulrich Andergassen,Roman Nawroth,Jürgen E. Gschwend,Margitta Retz +10 more
TL;DR: Circulating tumor cell counts are applicable as a prognostic molecular marker, especially in mCRPC patients harboring bone metastases with or without visceral metastases, and for clinical practice, mPC patients with elevated CTC counts in combination with short PSA-DT, high alkaline phosphatase and lactate dehydrogenase levels as well as low hemoglobin levels are at high risk of disease progression and limited OS.
126
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Peter Widschwendter,Thomas W. P. Friedl,Lukas Schwentner,Nikolaus DeGregorio,Bernadette Jaeger,A Schramm,Inga Bekes,Miriam Deniz,Krisztian Lato,Tobias Weissenbacher,Bernd Kost,Ulrich Andergassen,Julia Kathrin Jueckstock,Julia Neugebauer,Elisabeth Trapp,Peter A. Fasching,Matthias W. Beckmann,Andreas Schneeweiss,Ines Schrader,Brigitte Rack,Wolfgang Janni,Christoph Scholz +21 more
TL;DR: Severe obesity (BMI ≥ 40) significantly worsens prognosis in early breast cancer patients, particularly for triple-negative tumors.